Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.2
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ (3,984) $ (2,714) $ (7,424) $ (5,165)
General and administrative (4,066) (4,273) (7,999) (7,669)
Total operating expenses (8,050) (6,987) (15,423) (12,834)
Operating loss (8,050) (6,987) (15,423) (12,834)
Interest expense, net (766) (980) (1,805) (3,932)
Adjustments to fair value of derivatives 2,155 15,794 7,332 (74,309)
Other income, net 269 93 431 134
Total other income / (expense), net 1,658 14,907 5,958 (78,107)
Loss / (income) before income taxes (6,392) 7,920 (9,465) (90,941)
Income tax expense (343) (122) (770) (182)
Net (loss) / income and comprehensive (loss) / income (6,735) 7,798 (10,235) (91,123)
Net (loss) / income attributable to ordinary shareholders $ (6,735) $ 7,798 $ (10,235) $ (91,123)
Net (loss)/ income per share attributable to ordinary shareholders - basic $ (0.04) $ 0.04 $ (0.06) $ (0.63)
Net (loss) /income per share attributable to ordinary shareholders - diluted $ (0.04) $ 0.04 $ (0.06) $ (0.63)
Weighted average ordinary shares outstanding-basic 183,364,740 180,017,313 183,134,415 144,608,227
Weighted average ordinary shares outstanding-diluted 183,364,740 204,600,645 183,134,415 144,608,227